Limaye, V.Bundell, C.Hollingsworth, P.Rojana-Udomsart, A.Mastaglia, F.Blumbergs, P.Lester, S.2018-06-072018-06-072015Muscle and Nerve, 2015; 52(2):196-2030148-639X1097-4598http://hdl.handle.net/2440/112710Introduction: Inhibition of 3-hydroxy-3-methylglutaryl- coenzyme A reductase (HMGCR) with statins may trigger idiopathic inflammatory myositis (IIM) or immune-mediated necrotizing myopathy (IMNM). Anti-HMGCR antibodies have been detected in patients with IIM/IMNM. We aimed to determine the associations of anti-HMGCR in IIM/IMNM. Methods: Anti-HMGCR antibodies were detected by ELISA in sera from patients with IIM/IMNM. Results: Anti-HMGCR antibodies were detected in 19 of 207 patients with IIM/IMNM, and there was a trend toward an association with male gender (P50.079). Anti- HMGCR antibodies were associated strongly with statin exposure (OR539, P50.0001) and HLA-DRB1*11 (OR550, P<0.0001). The highest risk for development of anti-HMGCR antibodies was among HLA-DR11 carriers exposed to statins. Univariate analysis showed a strong association of anti- HMGCR antibodies with diabetes mellitus (P50.008), which was not confirmed by multiple regression. Among anti- HMGCR⁺ patients there was a trend toward increased malignancy (P50.15). Conclusions: Anti-HMGCR antibodies are seen in all subtypes of IIM and IMNM and are associated strongly with statin use and HLA-DR11.en© 2014 Wiley Periodicals, Inc.Antibodies; HMG-CoA reductase; immune-mediated necrotizing myopathy; muscle biopsy; myositis; statinsJournal article003002399910.1002/mus.245410003583795000062-s2.0-84937515701175501Limaye, V. [0000-0002-8142-9532]Lester, S. [0000-0003-3013-2701]